Novartis/Idenix To Co-Promote Hep C Treatment, But Side Effects Delay Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has exercised its option to license valopicitabine from Idenix in spite of gastrointestinal side effects seen in clinical trials.